Lincoln Educational Services Reports Results for Fourth Quarter and Full Year 2023
Conference Call Today at 10 a.m. ET PARSIPPANY, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) — Lincoln Educational Services Corporation (Nasdaq: LINC) […]
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements
FLORHAM PARK, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage […]
Tempest to Present at the 44th Annual TD Cowen Healthcare Conference
BRISBANE, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted […]
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
ARLINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) — KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, […]
Mission Produce™ to Release Fiscal First Quarter 2024 Financial Results on Monday, March 11, 2024
OXNARD, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) — Mission Produce, Inc. (Nasdaq: AVO) (“Mission” or the “Company”), a world leader […]
Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical […]
Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference
Oak Ridge, TN, Feb. 26, 2024 (GLOBE NEWSWIRE) — Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement […]
Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
• Net product revenue of $42.1M in 4Q and $50.7M for the year • New England Journal of Medicine publication of […]
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the […]
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
Data expected to be shared during March corporate update With SAD cohorts complete, MAD cohorts to begin dosing in March […]
